Apnimed Q2 2026 net income $125.9M; Oxnimbi PDUFA Feb 28, 2027
Apnimed reported Q2 2026 net income of $125.9M and ended the quarter with $172.8M in cash and cash equivalents. FDA accepted its NDA for AD109 (proposed Oxnimbi) with a PDUFA target date of Feb 28, 2027.